OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - MODERNA | Market Closed - Deutsche Boerse AG 03:44:19 2024-06-27 pm EDT | ||
| 5.86 EUR | -2.50% |
|
| Current month | -24.29% | ||
| 1 month | -40.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 5.86 | -2.50% |
| 24-06-26 | 6.01 | -16.99% |
| 24-06-25 | 7.24 | +0.28% |
| 24-06-24 | 7.22 | +3.44% |
| 24-06-21 | 6.98 | -0.43% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 03:44 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SB0Z1C |
| ISIN | DE000SB0Z1C9 |
| Date issued | 2020-06-08 |
| Strike | 59.03 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 38.57 € |
|---|---|
| Lowest since issue | 0.89 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.2
USD
Average target price
145.9
USD
Spread / Average Target
+20.36%
- Stock Market
- Certificates
- Certificat
